Pollux myeloma
WebJan 31, 2024 · Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies Haematologica . WebJul 19, 2024 · In the previously reported primary analyses, the addition of daratumumab to bortezomib plus dexamethasone (DVd) in the CASTOR trial and to Rd in the POLLUX trial seemed to significantly improve progression-free survival outcomes in patients with relapsed or refractory multiple myeloma. 34,35 An analysis of these phase III trials revealed …
Pollux myeloma
Did you know?
WebFeb 10, 2024 · Recent therapeutic advancements for patients with multiple myeloma (MM) have led to near doubling of their survival. 1 As long-term outcomes improve, the duration of time to data maturity in clinical trials lengthens for end points aimed at demonstrating clinically meaningful patient benefits, such as progression-free survival (PFS) and overall … WebMar 11, 2024 · Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab- Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J Clin Oncol. January 29, 2024. doi:10.1200/JCO.20. 01814
WebDec 10, 2024 · Patients with multiple myeloma have experienced a great improvement in survival over the past century because of the introduction of novel therapeutic ... plus …
WebJan 13, 2024 · The POLLUX trial (ClinicalTrials.gov Identifier: NCT02076009) included 569 patients with relapsed or refractory MM who had received at least 1 prior line of therapy. The patients were randomly ... WebDaratumumab was previously granted accelerated approval in November 2015 as monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a ...
Web一、概述. 随着自体造血干细胞移植（autologous hematopoietic stem cell transplantation，ASCT）和新药在一线治疗中的应用，多发性骨髓瘤（multiple myeloma，MM）患者的总生存（overall survival，OS）期已明显延长，但MM仍是一种不可治愈的疾病 [1,2] ，患者终将面临复发。 复发按照发生次数分为首次复发（第一次复发 ...
WebMar 3, 2014 · Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: … sims 4 igor hairWebPullorum disease in poultry is caused by the bacterium Salmonella pullorum. The disease affects mainly young chicks, but can also affect older chickens, and other domestic fowl. … rbz interbank rate 1 october 2022WebDec 12, 2024 · Daratumumab for Untreated Myeloma T he risk of multiple myeloma in- ... [POLLUX trial]18) significantly prolonged progression-free survival and induced higher response rates. These sims 4 idol challengeWebOct 6, 2016 · Conclusions. The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma ... rbz interbank rate 22 february 2023WebJan 30, 2024 · Leukemia - Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, … rbz interbank rate 2 october 2022WebJun 15, 2016 · COPENHAGEN—The combination of daratumumab, lenalidomide, and dexamethasone (DRd) could become a new standard of care for patients with relapsed or refractory multiple myeloma (MM), according to a speaker at the 21st Congress of the European Hematology Association. In the phase 3 POLLUX study, DRd rbz interbank rate 19 february 2023WebApr 1, 2024 · Methods: MRD was assessed via next-generation sequencing (10-5) at suspected complete response (CR), 3 and 6 months following confirmed CR (POLLUX), 6 and 12 months following the first dose (CASTOR), and every 12 months post-CR in both studies. Sustained MRD negativity (≥ 6 or ≥ 12 months) was evaluated in the intention-to … rbz interbank rate 19 may 2022